CION Ameerpet
Double-hit lymphoma is an aggressive high-grade B-cell lymphoma defined by MYC together with BCL2 (or BCL6) gene rearrangements. This guide explains the markers, how it differs from ordinary DLBCL, and how CION's haematology team diagnoses and treats it.
Double-hit lymphoma is an aggressive B-cell non-Hodgkin lymphoma in which the tumour cells carry two specific genetic changes at once — a rearrangement of the MYC gene together with a rearrangement of BCL2 (or, less often, BCL6). In the current WHO classification this sits inside the category of high grade b cell lymphoma with MYC and BCL2 rearrangements. When all three genes are rearranged, it is called a "triple-hit" lymphoma.
The important thing to understand is that a myc bcl2 lymphoma can look almost identical to an ordinary diffuse large B-cell lymphoma (DLBCL) under the microscope. The difference is purely genetic — and it is found only through molecular and genetic testing on the biopsy tissue. Because these gene changes drive faster, more resistant growth, double-hit disease is treated as a distinct, higher-risk category.
This page explains what the MYC and BCL2 markers mean, how the disease is diagnosed and treated, and where it fits among the other B-cell lymphomas. For the full picture, see our Lymphoma hub and our Lymphoma Treatment in Hyderabad page.
A double-hit lymphoma cannot be told apart from ordinary large B-cell lymphoma by looking at the cells alone — it is defined by its genes. This is why NCCN and ESMO guidelines recommend that every newly diagnosed aggressive B-cell lymphoma has FISH testing for MYC, BCL2 and BCL6. Without that molecular test, a higher-risk double-hit lymphoma can be mistaken for a standard DLBCL and under-treated. (Source: NCCN B-Cell Lymphomas guideline and ESMO Clinical Practice Guidelines for diffuse large B-cell lymphoma.)
These are genes inside the lymphoma cell. They are testing findings on your biopsy — not separate cancers. Together they explain why the disease behaves aggressively.
| Marker | What it is | What a rearrangement does |
|---|---|---|
| MYC | A master "growth switch" gene | Drives the cell to divide rapidly — the core feature of a double-hit lymphoma |
| BCL2 | A survival gene that blocks cell death | Stops abnormal cells from being cleared, so the lymphoma resists dying |
| BCL6 | A regulator of B-cell development | Can pair with MYC as the "second hit"; with MYC + BCL2 makes a "triple-hit" lymphoma |
A "double-hit" means MYC plus BCL2 or BCL6; a "triple-hit" means all three. These patterns are confirmed by FISH testing on tissue, reviewed by a haematopathologist. See our molecular & genetic testing page for how the results are produced.
Most large B-cell lymphomas are standard DLBCL. A smaller group carry the double-hit genetics — and that changes everything about how they are managed.
Under the microscope a double-hit lymphoma often looks like a routine DLBCL. Only FISH molecular testing for MYC, BCL2 and BCL6 reveals the double-hit pattern — which is why guidelines insist on testing every aggressive B-cell lymphoma.
The combination of a MYC and a BCL2 (or BCL6) rearrangement drives quicker growth and a higher chance of spread, including to sites outside the lymph nodes. This is why nodes can enlarge rapidly and symptoms appear over weeks rather than months.
Because of its biology, double-hit disease is generally more resistant than standard DLBCL and published series report lower remission rates. It is therefore risk-stratified and monitored more intensively — never treated as an "average" large B-cell lymphoma.
Getting the genetics right up front, and having the plan set by an experienced lymphoma team and tumour board, is what most improves the odds. This is a diagnosis where a prompt, accurate second opinion genuinely matters.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just been told your lymphoma is "double-hit" or high-grade, want to understand what MYC/BCL2 means, or need a second opinion before treatment starts? CION's haematology team is here.
Because double-hit lymphoma grows quickly, its symptoms often develop over weeks rather than months. They overlap with those of other aggressive lymphomas, so the signs alone cannot tell you the genetic subtype — only a biopsy and molecular testing can. Common features include:
These symptoms have many ordinary causes, and most swollen nodes are not lymphoma. But swellings that are rapidly growing, persistent, or come with B symptoms should be assessed promptly. Speak to a CION lymphoma specialist if you have these signs or a confirmed high-grade lymphoma.
Confirming a double-hit / high-grade B-cell lymphoma — and separating it from ordinary DLBCL — follows a step-by-step pathway. CION performs the biopsy, arranges the molecular testing, and reviews every result directly.
The diagnosis begins with a biopsy of an enlarged node or affected tissue, examined by a haematopathologist. This confirms it is a large/high-grade B-cell lymphoma and provides the tissue needed for the molecular tests that follow. Imaging can suggest lymphoma, but only tissue confirms it.
On the biopsy tissue, FISH testing for MYC, BCL2 and BCL6 is performed. This is the only way to identify a double-hit or triple-hit lymphoma, because these tumours look like ordinary DLBCL down the microscope. Immunohistochemistry for the MYC and BCL2 proteins may be used first to flag cases needing FISH. NCCN and ESMO both recommend this testing on all aggressive B-cell lymphomas. CION arranges MYC/BCL2/BCL6 testing as standard — see our molecular and genetic testing in lymphoma page.
Once the type is confirmed, a PET-CT scan maps where the disease is, and a bone-marrow examination checks for involvement. Because double-hit lymphoma can reach sites outside the nodes, careful staging is important. All of this is reviewed by CION's multidisciplinary tumour board before any treatment decision.
The MYC gene is one of the most powerful growth-driving genes in the human cell. When it is rearranged together with BCL2 — a gene that normally blocks cell death — the lymphoma both grows faster and resists being cleared, which is exactly why double-hit disease behaves more aggressively than ordinary large B-cell lymphoma. Because of this, NCCN and ESMO advise that MYC/BCL2/BCL6 testing guides risk assessment before treatment is finalised — the molecular test, not the microscope alone, defines the plan.
The plan depends on stage, age, fitness and how the disease responds early. Every case is reviewed by CION's multidisciplinary tumour board and follows NCCN and ESMO-aligned protocols. The main building blocks are:
Because double-hit lymphoma is aggressive, it is usually treated with more intensive systemic therapy than standard large B-cell lymphoma, combining chemotherapy with an anti-CD20 monoclonal antibody (a therapy directed at the CD20 marker on B-cells). CION's medical oncology and haematology team delivers this chemotherapy and antibody therapy in-house. Specific drug names and regimens are individualised — those details are covered on our Lymphoma Treatment in Hyderabad page.
For selected sites — for example bulky disease or a specific residual area — precision radiation therapy (IMRT) may be added. CION delivers radiation directly, shaping the beam to the target while sparing healthy tissue.
Because high-grade lymphomas can occasionally reach the central nervous system, the team assesses this risk and manages it as part of the plan. Response is tracked with repeat imaging so treatment can be adjusted quickly.
If the disease relapses or does not respond, advanced options such as stem-cell transplant or CAR-T cell therapy may be considered. These are coordinated through accredited partner facilities rather than delivered in-house, with CION managing the referral, work-up and ongoing care around them. This is also relevant to relapsed or refractory large B-cell lymphoma.
Double-hit / high-grade B-cell lymphoma is aggressive, but it is treated with the intent to cure, and a meaningful proportion of patients reach long-term remission. Because it is higher-risk than ordinary large B-cell lymphoma, published series report lower remission rates than standard DLBCL — which itself sits around 60–70% overall survival in published data, while aggressive lymphomas as a broad group span a wide range and the more favourable Hodgkin lymphoma sits around 80–90%. These figures are drawn from published series and are averages only.
Figures vary considerably by individual — stage, age, fitness and early response all matter — and no statistic should be read as a personal prediction. What consistently improves outcomes is prompt, accurate molecular diagnosis, a plan set by an expert tumour board, and close monitoring. For related subtypes, see DLBCL survival & prognosis and Burkitt lymphoma, another very fast-growing MYC-driven B-cell lymphoma.
Double-hit lymphoma sits within a family of B-cell lymphomas. These related conditions are diagnosed with the same molecular-testing approach.
An aggressive B-cell lymphoma diagnosis moves quickly, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service, and can arrange care through the best lymphoma hospital in Hyderabad setting. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if MYC/BCL2/BCL6 testing has not yet been arranged on your biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Double-hit lymphoma is an aggressive B-cell lymphoma in which the tumour cells carry two specific genetic rearrangements at the same time — a rearrangement of the MYC gene together with a rearrangement of BCL2 (or, less often, BCL6). In the current WHO classification this is placed within "high-grade B-cell lymphoma with MYC and BCL2 rearrangements". Because these gene changes drive faster growth, the disease behaves more aggressively than ordinary large B-cell lymphoma and is treated as a distinct, higher-risk category. The label comes from molecular and genetic testing — usually a FISH test on the biopsy tissue — not from the appearance under the microscope alone.
On the microscope, a high-grade B-cell lymphoma can look almost identical to a standard diffuse large B-cell lymphoma (DLBCL). The difference is genetic: high-grade B-cell lymphoma is defined by having a MYC rearrangement together with a BCL2 and/or BCL6 rearrangement, which makes it grow and spread more quickly. This is why every large B-cell lymphoma should have FISH testing for these genes at diagnosis, per NCCN and ESMO guidance. Identifying it matters because it changes risk assessment, the intensity of the plan, and how closely the disease is monitored. If your report simply says "DLBCL", it is reasonable to ask whether MYC/BCL2/BCL6 testing was done.
MYC and BCL2 are genes inside the lymphoma cell. When a report describes a MYC BCL2 lymphoma or a "double-hit" pattern, it means testing found the MYC gene rearranged alongside a rearranged BCL2 gene. MYC is a powerful driver of cell growth; BCL2 blocks the normal signal that would make an abnormal cell die. Together they let the lymphoma grow quickly and resist being cleared. A "triple-hit" lymphoma carries MYC, BCL2 and BCL6 rearrangements. These are testing findings on the biopsy — not a separate organ or a new cancer. Our molecular and genetic testing page explains how these results are produced and what each marker adds.
Diagnosis starts with a biopsy of an enlarged node or affected tissue, examined by a haematopathologist. Because double-hit lymphoma cannot be told apart from ordinary large B-cell lymphoma by appearance alone, the key step is FISH (fluorescence in-situ hybridisation) testing for MYC, BCL2 and BCL6 rearrangements. Immunohistochemistry for the MYC and BCL2 proteins may flag cases that need FISH. Staging then uses a PET-CT scan and often a bone-marrow examination. CION performs the biopsy, arranges the molecular and genetic testing, and reviews every result at a multidisciplinary tumour board before a plan is set. Getting the double-hit status confirmed early is the single most important diagnostic step.
Double-hit / high-grade B-cell lymphoma is aggressive, but it is treated with the intent to cure, and a meaningful proportion of patients do achieve long-term remission. Because it is higher-risk than ordinary large B-cell lymphoma, published series report lower remission rates than standard DLBCL (which sits around 60–70% overall per published data), and outcomes depend heavily on stage, age, fitness and how the disease responds early on. Figures vary by individual and should never be read as a personal prediction. What consistently improves outcomes is prompt, accurate diagnosis, treatment planned by an expert tumour board, and close monitoring. Discuss your specific situation with a CION specialist rather than relying on general statistics.
Because of its aggressive biology, double-hit lymphoma is usually managed with more intensive systemic (drug) therapy than standard large B-cell lymphoma, typically combining chemotherapy with an anti-CD20 monoclonal antibody. CION delivers this chemotherapy and antibody therapy, radiation (IMRT) where indicated, biopsy, bone-marrow examination and all supportive care directly. If the disease relapses or does not respond, options such as stem-cell transplant or CAR-T cell therapy are arranged in a coordinated way through accredited partner facilities. Specific drug names and regimens are individualised and are covered on our Lymphoma Treatment in Hyderabad page. Every case follows NCCN and ESMO-aligned protocols and is reviewed by our tumour board.
Because double-hit / high-grade B-cell lymphoma behaves differently from ordinary large B-cell lymphoma, its identification changes how the disease is risk-stratified, how intensively it is treated, and how closely it is followed. Both NCCN and ESMO recommend FISH testing for MYC, BCL2 and BCL6 on all newly diagnosed aggressive B-cell lymphomas precisely so that double-hit cases are not missed. Confirming the status up front avoids under-treating an aggressive disease. If you are seeking a second opinion, it is worth checking that this molecular testing was performed and reviewed. CION arranges MYC/BCL2/BCL6 testing as standard on aggressive B-cell lymphoma tissue.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.